A team of researchers have developed a tailored virus that destroys brain tumour stem cells that resist other treatment and cause re-growth of cancer after surgery.
Delta-24-RGD developed by Fueyo and colleagues was tested against the most aggressive brain tumour Glioblastoma multiforme that is highly resistant to radiation and chemotherapy and is also invasive that even surgery never eliminates it almost all the time.
"We have shown first in lab experiments and then in stem cell-derived human brain cancer in mice, that we have a tool that can target and eliminate the cells that drive brain tumours," says co-senior author Juan Fueyo, M.D., associate professor in M. D. Anderson's Department of Neuro-Oncology.
Fueyo and colleagues developed Delta-24-RGD to prey on a molecular weakness in tumours and altered the virus so it could not replicate in normal tissue. They showed in a study r in 2003 that the virus eliminated brain tumours in 60 percent of mice who received injections directly into their tumours. The virus spreads in a wave through the tumours until there are no cancer cells left, and then it dies.
Since 2004 scientists have found that brain tumours are driven by haywire stem cells that replicate themselves, differentiate into other types of cells, and bear protein markers like normal stem cells.
"Research has shown that these cancer stem cells are the origin of the tumour, that they resist the chemotherapy and radiation that we give to our patients, and that they drive the renewed growth of the tumour after surgery," Fueyo said. "So we decided to test Delta-24-RGD against glioma stem cells and tumours grown from them," Fueyo added.
The research team led by Fueyo, co-senior author Frederick Lang, M.D., professor in M. D. Anderson's Department of Neurosurgery, and first author Hong Jiang, Ph.D., instructor in neuro-oncology, derived four brain tumour stem cell lines from four specimens of glioblastoma multiforme. All four lines exhibited the characteristics and protein signatures of stem cells. Delta-24 succeeded in killing all four types in the lab.
Next, the researchers grafted the stem cell lines into the brains of mice and treated the resultant tumours with injections of Delta-24-RGD. Untreated mice had a mean survival time of 38.5 days, while treated mice had a mean survival of 66 days. Two of the eight treated mice survived for 92 days, until the end of the experiment, with no neurological symptoms. "It's important in animal models to see improvement in survival in the majority of animals, but to have some be cured and survive a long time without neurological symptoms is very rare," Fueyo said.
"We have to be cautious, because an animal model doesn't fully represent humans, but the tumours grown by these stem cells closely resemble the tumours we see in our patients, which is an exciting finding in itself," Fueyo added.
Tumours in other mouse models tend to be round and self-contained, explains co-senior author and Frederick Lang, M.D., professor in M. D. Anderson's Department of Neurosurgery. Malignant tumours in patients are never round, they invade other tissues and delve deeply into the brain. The cancer stem cell-derived tumours in these experiments have the irregular shape and invasive characteristics of their human counterparts.
"That similarity to the human tumour is encouraging,. And it's also encouraging that we got basically the same results with Delta-24-RGD in this experiment that we got in our earlier experiment using other tumor models," Lang said.
Delta-24-RGD exploits the fact that a protein called retinoblastoma (Rb) is either missing or defective in brain tumours. Rb normally guards against both the proliferation of cancerous cells and against viral infection. So the virus has an easier time invading tumours and replicating in its cells. Adenoviruses attacking normal cells employ their own protein, E1A, to counteract retinoblastoma's defensive measures. To keep Delta-24-RGD out of normal cells, Fueyo and colleagues deleted a small part of the gene that produces E1A.
The paper shows that Delta-24-RGD forces tumour cells to devour themselves until they die. This self-cannibalization, called autophagy, occurs when a cell forms a membrane around part of its cytoplasm or an organelle and then digests the contents, leaving a cavity. A cell that dies from autophagy is riddled with cavities.
Cells normally employ autophagy temporarily to survive when nutrients are short, to recycle components to form new organelles, or to fend off viral or bacterial infection. In cancer research, there is evidence both that autophagy is a form of programmed cell death triggered to prevent the replication of damaged cells and that cancer cells in some instances employ it to survive attack.
"Our next experiments will address whether the cell kills itself or dies defending itself against the virus. Sure, the cell dies either way, but the distinction is important because the virus could be redesigned to either fuel or block autophagy to make it more effective. The autophagic protein Atg5 is heavily expressed in the dead tumour cells, making it a potential biomarker of the virus' effectiveness," Fueyo said.
A clinical quality version of Delta-24-RGD has been manufactured by the National Cancer Institute and an independent consultant has completed a toxicology assessment. An Investigational New Drug Application to proceed with a phase I clinical trial is expected to be filed with the U.S. Food and Drug Administration in September. A clinical trial could began as early as this fall.
The study is published in the Sept. 18 edition of the Journal of the National Cancer Institute.